Latest Spinal muscular atrophy Stories
These funds were awarded as part of Families of SMA’s basic research grant program.
On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx CARLSBAD, Calif., Feb.
--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Use of Genetic Variants Improves Detection of SMA Carriers in Clinical Test that will be Broadly Licensed to Testing Labs Worldwide New York, NY (PRWEB) February
Program Created by FightSMA and Gwendolyn Strong Foundation to Advance Spinal Muscular Atrophy Research Washington, DC (PRWEB) January 22, 2014 The "FightSMA
SOUTH PLAINFIELD, N.J., Jan. 22, 2014 /PRNewswire/ -- PTC Therapeutics, Inc.
The organizations conceived the awards in order to draw strong, innovative talent into Spinal Muscular Atrophy research. Alexandria, VA (PRWEB) January 15, 2014
A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults.
It describes the scientific strategy behind Antisense Drugs.
- Of or relating to good digestion.